Selective CAR-T targets IGHV4-34, sparing healthy immunity in lymphoma mice
TL;DR Summary
A CART4-34 CAR-T therapy targets the IGHV4-34 gene in B-cell cancer, destroying lymphoma cells in mice as effectively as CD19 CAR-T while sparing healthy B cells and avoiding immune suppression; the approach could also be used to treat autoimmune conditions such as lupus, but human trials are needed.
Topics:science#autoimmune-diseases#car-t-therapy#diffuse-large-b-cell-lymphoma#ighv4-34#immune-suppression#medicine
Reading Insights
Total Reads
0
Unique Readers
15
Time Saved
5 min
vs 5 min read
Condensed
95%
1,001 → 48 words
Want the full story? Read the original article
Read on Nature